Current Clinical Trials

ADVANCE (ESTIMATED TO OPEN IN MAY)
Contact: Grace Kim-Lee 215-898-3981  Leeg@uphs.upenn.edu

        A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C

SyNCH II (Hepatitis C)
Contact: Amy Micheli 215-898-2450  michelia@uphs.upenn.edu        
       A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase II Study to Assess the Safety and Efficacy of a Standardized Orally Administered Silymarin Preparation (Legalon) for the Treatment of Non-Cirrhotic Patients with Chronic Hepatitis C Who Failed Conventional Antiviral Therapy

SyNCH II (NASH)
Contact: Amy Micheli 215-898-2450  michelia@uphs.upenn.edu         
      A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase II Study to Assess the Safety and Efficacy of a Standardized Orally Administered Silymarin Preparation (Legalon) for the Treatment of Non-Cirrhotic Patients with Non-Alcoholic Steatohepatitis

ProPeach  (ESTIMATED TO ENROLL IN SUMMER)
Contact: Amy Micheli 215-898-2450  michelia@uphs.upenn.edu

        A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Food Effect of RO5024048 in Healthy Volunteers and in Patients with Chronic HCV Infection of Genotype 1